Office-Use Syringes, a Dye-Free Suspension, and Overseas API
A Mississippi community pharmacy with a small nonsterile compounding area receives two requests on the same morning. A dermatology clinic faxes an order for 60 prefilled syringes of triamcinolone acetonide 40 mg/mL intralesional suspension, for office use, with no patient names and no individual prescriptions, and asks for a bulk price. Separately, a pediatrician sends a patient-specific prescription for amoxicillin 250 mg/5 mL oral suspension, dye-free, for a 4-year-old with a documented reaction to FD&C Red No. 40; the commercial suspension contains that dye, and the prescriber has written on the face of the prescription that the dye-free formulation is clinically necessary. Meanwhile the purchaser reports he can buy a kilogram of triamcinolone acetonide API from an overseas supplier at a good price, and that a certificate will be included.
1. Can the pharmacy compound the 60 triamcinolone syringes for office use?
Read the worked answer
Two problems, each independently fatal under the federal 503A framework (21 U.S.C. 353a).
No patient-specific prescription. Section 503A compounding must be based on a prescription for an identified patient pursuant to a valid prescriber-patient relationship. Limited anticipatory compounding based on a documented history of prescriptions is one thing; 60 syringes ordered by a clinic for unspecified future patients is office-use distribution, which is not authorized by 353a and is governed by state law - do not assume Mississippi permits it.
Essentially a copy. Triamcinolone acetonide 40 mg/mL intralesional suspension is commercially available. Compounding an essentially copy of a commercially available drug is prohibited unless the prescriber determines that a change produces a significant difference for the identified patient (353a(b)(1)(D)). A clinic purchasing in bulk cannot make that determination for unidentified patients.
The compliant alternatives: the clinic buys the FDA-approved product, or the order goes to a registered 503B outsourcing facility, which may compound for office use without patient-specific prescriptions.
2. May the pharmacy compound the dye-free amoxicillin suspension, and how should it be made?
Read the worked answer
Yes. This fits the narrow exception to the essentially-a-copy prohibition: 21 U.S.C. 353a(b)(1)(D) allows compounding a copy of a commercially available drug when the prescriber determines that a change made for an identified patient produces a significant difference for that patient. Here the prescriber documented a dye reaction and the clinical need on the prescription face - keep that documentation with the compounding record.
Sourcing: compounding from an FDA-approved finished product (amoxicillin capsules or an approved powder) is the cleanest route and avoids the bulk-substance analysis. If a bulk API is used instead, it must comply with USP/NF monograph standards, come with a valid certificate of analysis, and be manufactured by an FDA-registered establishment; bulk substances must also appear on the FDA 503A bulks list or be a component of an approved drug.
Beyond-use dating: assign a BUD per USP <795> - a nonpreserved aqueous oral suspension is typically limited to 14 days refrigerated. Do not simply copy the commercial product's expiration date.
3. What is your response to the overseas API offer?
Read the worked answer
Decline. Under 353a(b)(1)(A), bulk drug substances must meet USP or NF monograph standards, be accompanied by valid certificates of analysis, and be manufactured by an establishment registered with FDA. An unregistered overseas supplier with a generic certificate cannot satisfy that, so anything made from it is adulterated and the pharmacy is exposed on both the FD&C Act and Board rules.
Verify, do not assume: (1) the supplier's FDA registration status; (2) that the substance appears on FDA's 503A bulks list; (3) a current, substance-specific certificate of analysis with the supplier's identity and lot; (4) USP compliance. Document all four in the compounding record.
A good price on API is a classic pathway to an adulterated compounded preparation, and it is the pharmacist - not the purchaser - who signs the compounding record.